Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MRT's revenue for the
three
months ended in Mar. 2026 was 円907 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was 円4,102 Mil.
MRT's Revenue per Share for the
three
months ended in Mar. 2026 was 円164.64.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円729.84.
Warning Sign:
MRT Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of MRT was 25.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -21.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 3.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 19.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 12 years, MRT's highest 3-Year average Revenue per Share Growth Rate was 58.70% per year. The lowest was -21.90% per year. And the median was 12.00% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
MRT Revenue Related Terms
MRT Revenue Historical Data
* Premium members only.
The historical data trend for MRT's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, MRT's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MRT Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MRT's Revenue distribution charts can be found below:
* The bar in red indicates where MRT's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円4,102 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MRT (TSE:6034) has a Revenue of 円4,102 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on MRT and its competitors.
Is MRT's Revenue too high?
MRT's current Revenue is 円4,102 Mil. Overall, MRT has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MRT's Revenue compare to HCA and THC?
MRT's Revenue of 円4,102 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on MRT and its competitors. MRT's current Revenue is 円4,102 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MRT stock overvalued right now?
Based on GuruFocus' analysis, MRT (TSE:6034) is currently considered Fairly Valued. The stock's GF Value™ is 円614.77, compared to a current price of 円636.00 — trading 3.5% above its estimated fair value. The current Revenue is 円4,102 Mil. MRT's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For MRT (TSE:6034), the current Revenue is 円4,102 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MRT (TSE:6034) Overvalued in 2026?
Based on GuruFocus' analysis, MRT stock appears to be overvalued.
The current stock price of 円636.00 is trading 3.5% above its estimated GF Value™ of 円614.77.
GuruFocus considers MRT to be Fairly Valued.
Key valuation signals for TSE:6034:
Revenue: 円4,102 Mil
GF Value™: 円614.77 vs. price of 円636.00 (3.5% above fair value)
No single metric tells the full story. See the TSE:6034 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MRT Inc engages in the business of medical personnel placement services through the Internet. It provides part-time and full-time physician referral services through the physician referral site, as well as part-time job referral, job change introduction services to nurses, pharmacists, clinical laboratory technicians, clinical engineers, and radiologists. Further, the company engages in the research and development of analytical and analytical methods for various biological samples, such as microorganisms, blood, proteins, and genes; and research and development, manufacture, and sale of medical and medical examination equipment, and analytical instruments.
63GF Score
Get the complete analysis for TSE:6034
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6034 has been successfully added to your 
